On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Long Covid remains a major concern for millions worldwide. After an infection caused by the SARS-CoV-2 virus, many ...

Scientists have found that receiving a COVID-19 booster shot in the same arm as the initial dose triggers a faster and more effective immune response, thanks to primed macrophages in nearby lymph ...

In a major step toward combating Long Covid, a team of US scientists has launched a clinical trial to evaluate the ...

University of Hyderabad and Krismo Biosciences collaborate to develop antibody-based therapies for infectious diseases and toxins.

The following is a summary of “Long Term Effects of COVID-19 in Primary Immunodeficiency Patients: An IPOPI Worldwide Survey, ...

US scientists are undertaking a clinical trial to decode the efficacy of a long-acting antibody against Long Covid -- a condition that affects at least 65 million people worldwide. Long Covid affects ...

Christianity Today spoke with five Filipino children’s book authors about the challenges and blessings of writing for the ...

Using the blood of a man with a unique snakebite history, researchers developed an antivenom cocktail that neutralized toxins ...

Our bodies depend on an alphabet of vitamins that promote the development, growth and function of cells, including immune ...

A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential ...

呼吸道传染病如 COVID-19 和流感严重影响社会，现有肌肉注射疫苗在诱导局部免疫反应方面存在局限。研究人员开展了鼻内亚单位疫苗平台的研究，该疫苗可诱导全身和黏膜抗体免疫。这为呼吸道病原体疫苗研发提供了新方向。